Physician profile
Eric Christopher Evans
NPI 1871791434
$8,052.84
in general payments reported to CMS, 2019-2025
40 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,137 · 2020: $272 · 2021: $1,286 · 2022: $1,357 · 2023: $842 · 2024: $985 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,002.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,056.15 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $872.91 | 2019-2025 | |
| Pfizer INC. | $721.78 | 2019-2025 | |
| Amgen INC. | $721.48 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $476.46 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $471.37 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Merck Sharp & Dohme LLC | $395.99 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $377.44 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.44 | 2019-2025 | Jardiance, Synjardy, Jentadueto |
| Janssen Pharmaceuticals, INC | $349.33 | 2019-2022 | |
| Esperion Therapeutics, INC. | $279.29 | 2021-2025 | Nexletol |
| Corcept Therapeutics | $203.18 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $173.89 | 2019-2022 | |
| Allergan, INC. | $164.54 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $161.30 | 2020-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.